Skip to main content
TipRanks
Go Ultimate75% OFF

Sedana Medical AB (SEDANA) AI Stock Analysis

1 Followers
SE:SEDANA

Sedana Medical AB

(Nasdaq OMX AB:SEDANA)

Select Model
Rating:49Neutral
Price Target:SEK 8.50â–¼(-1.73% Downside)
Action:reiterated
Date:10/24/26

The score is constrained primarily by continued operating losses and negative cash flow, despite a very strong balance sheet and substantial revenue growth. Weak valuation and slightly negative technical momentum further limit the outlook.

Positive Factors
Strong Revenue GrowthRevenue growth of approximately 152% indicates strong adoption and expanding commercial traction for Sedana Medical’s product platform. If this momentum persists, greater scale can support broader hospital penetration, operating leverage, and a stronger foundation for eventual profitability.
Negative Factors
Persistent UnprofitabilityOngoing operating and net losses show that strong revenue growth has not yet translated into sustainable profitability. Continued losses can limit internally funded investment, delay returns to shareholders, and leave the business dependent on its capital base while it scales.

Sedana Medical AB (SEDANA) vs. iShares MSCI Sweden ETF (EWD)

-30%-20%-10%0%10%20%30%40%SE:SEDANA-16.67%EWD+8.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 859.26M
Dividend Yield
―
Average Volume (3M)
103.92K
Price to Earnings (P/E)
-24.9
Beta (1Y)
0.76
Revenue Growth
0.42%
EPS Growth
15.03%
Country
Sweden
Employees
116
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Sedana Medical AB Business Overview & Revenue Model

Company Description

Sedana Medical AB (publ) is a medical technology firm that engineers, promotes, and distributes healthcare devices both within Sweden and across global markets. Its product portfolio includes the Sedaconda ACD-L and Sedaconda ACD, single-use medical...

Sedana Medical AB Financial Statement Overview

Summary

The balance sheet is a major strength, with minimal debt and substantial equity. However, persistent EBIT and net losses, negative operating cash flow, and negative free cash flow materially weaken the financial profile despite strong revenue growth and improving cash-flow losses.

Income Statement

42Neutral

Balance Sheet

88Very Positive

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue198.44M200.23M178.75M153.87M122.86M159.15M
Gross Profit142.03M142.71M126.14M108.98M86.07M106.71M
EBITDA-5.39M-10.12M-4.03M-51.67M-48.78M-43.51M
Net Income-34.54M-59.24M-10.67M-59.61M-73.51M-57.97M
Balance Sheet
Total Assets929.69M954.46M1.02B1.01B1.08B1.17B
Cash, Cash Equivalents and Short-Term Investments39.72M90.98M193.96M381.80M607.74M836.18M
Total Debt6.27M4.70M5.92M4.31M8.74M8.87M
Total Liabilities52.29M53.68M61.17M44.06M52.43M66.12M
Stockholders Equity877.40M900.78M958.26M970.00M1.03B1.10B
Cash Flow
Free Cash Flow-60.52M-75.19M-186.77M-206.95M-253.22M-151.48M
Operating Cash Flow-13.20M-12.78M-11.77M-38.06M-115.43M-41.22M
Investing Cash Flow-56.58M-63.03M-44.67M-321.96M-137.78M-110.25M
Financing Cash Flow-4.64M-4.04M-3.57M-4.86M-1.51M605.07M

Sedana Medical AB Technical Analysis

Technical Analysis SentimentNegative
Last Price8.65

Price Trends

50DMA9.60Negative
100DMA9.94Negative
200DMA9.58Negative

Market Momentum

MACD-0.22Positive
RSI37.03Neutral
STOCH7.70Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SEDANA, the sentiment is Negative. The current price of 8.65 is below the 20-day moving average (MA) of 9.31, below the 50-day MA of 9.60, and below the 200-day MA of 9.58, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 37.03 is Neutral, neither overbought nor oversold. The STOCH value of 7.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SEDANA.

Sedana Medical AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:SEDANA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:GETI.BSE:GETI.B67NeutralSEK 75.39B26.649.13%1.72%-3.90%37.73%
SE:XVIVOSE:XVIVO64NeutralSEK 6.18B47.955.89%―17.83%330.94%
SE:SEZISE:SEZI55NeutralSEK 510.16M-5.23-35.44%―18.56%28.11%
SE:BRAINSE:BRAIN54NeutralSEK 442.26M-12.12-19.29%―0.04%34.45%
SE:BACTI.BSE:BACTI.B53NeutralSEK 520.40M82.501.93%―-0.51%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:SEDANASE:SEDANA49NeutralSEK 859.26M-24.90-3.88%―0.42%15.03%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%SE:SEDANASE:GETI.BSE:SEZISE:XVIVOSE:BACTI.BSE:BRAINDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:SEDANA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:SEDANASedana Medical AB8.65-1.35-13.50%
SE:GETI.BGetinge AB (UK)276.8071.2534.66%
SE:SEZISenzime AB3.25-1.81-35.87%
SE:XVIVOXvivo Perfusion AB196.1016.309.07%
SE:BACTI.BBactiguard Holding AB14.85-1.50-9.17%
SE:BRAINBrainCool AB1.120.5493.77%

Sedana Medical AB Corporate Events

Sedana Medical Returns to Sales Growth but Continues to Invest Heavily in Expansion

Oct 22, 2026

Sedana Medical reported third-quarter 2026 net sales of SEK 44.2 million, up 7 percent year-on-year, with gross margin slipping to 70 percent as contract manufacturing accounted for a larger share of revenue and prior-year margins benefited from a on...

Sedana Medical Sets Date for Q3 2026 Interim Report and Investor Presentation

Oct 15, 2026

Sedana Medical AB will publish its interim report for the third quarter of 2026 on October 22 at around 07:00 CET and follow up with an English‑language presentation at 13:30 CET the same day. Chief executive Johannes Doll, together with the company’...

Sedana Medical Sets 2027 AGM Nomination Committee Representing Major Shareholders

Oct 14, 2026

Sedana Medical AB has appointed its Nomination Committee for the 2027 Annual General Meeting, in line with its governance principles that give the three largest shareholders, together with the Chairman of the Board, responsibility for preparing key A...

Sedana Medical Secures FDA PDUFA Date for Inhaled ICU Sedation Therapy

Aug 31, 2026

Sedana Medical AB has received a U.S. Food and Drug Administration Prescription Drug User Fee Act target action date of April 16, 2027 for its New Drug Application covering isoflurane delivered via the Sedana Medical ACD Delivery System for sedation...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 24, 2026